Prima BioMed to Host Investor Days in Australia
(firmenpresse) - SYDNEY, AUSTRALIA -- (Marketwire) -- 01/23/13 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", "the Company") is pleased to announce upcoming investor days at several major Australian cities in February.
Prima CEO, Matthew Lehman will host the sessions, to be held in Sydney, Melbourne, Brisbane and Perth, in the week commencing 4 February 2013.
Mr. Lehman will provide an update on the Company's business and attendees will have an opportunity for Q&A.
Parmelia Hilton Hotel, 14 Mill St, Perth
10.00am - 11.30am local time
Westin Melbourne Hotel, 205 Collins St, Melbourne
10.30am - 12.00noon local time
Hilton Brisbane Hotel, 190 Elizabeth St, Brisbane
10.00am - 11.30am local time
Radisson Blu Hotel, 27 O'Connell St, Sydney
10.30am - 12.00noon local time
Shareholders and other interested parties are kindly requested to help assure appropriate accommodations by sending an RSVP by email to and identify the city of attendance by Friday 1st February.
Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.
Ms. Jessica Brown
Prima BioMed Ltd.
+1 (919) 710-9061
Mr. James Moses
Mandate Corporate
+61 (0) 420 991 574
Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505-52
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 23.01.2013 - 19:15 Uhr
Sprache: Deutsch
News-ID 1190006
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
SYDNEY, AUSTRALIA
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 133 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Prima BioMed to Host Investor Days in Australia
"
steht unter der journalistisch-redaktionellen Verantwortung von
Prima BioMed (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
